"Take More Risks, Fail Earlier" Says Asset-Hunting Novo Nordisk CEO
Novo Nordisk's CEO tells Scrip why the Danish group's R&D approach must embrace risk earlier to ensure "differentiated" products in an increasingly competitive world.
You may also be interested in...
Being able to move therapeutic molecules for diabetes and other metabolic diseases into the CNS is the aim of a research collaboration and option agreement between Novo Nordisk and the six-year-old US biotech, Ossianix.
Lars Rebien Sørensen is retiring as CEO of Novo Nordisk by the end of the year, with executive vice president and corporate development head Lars Fruergaard Jørgensen stepping up as his successor.
EXACT-Tx will use funds from a NOK155m private placing to harness ultrasound in precision therapeutic targeting across a variety of indications and product classes.